• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PainReform Ltd. (Amendment)

    1/23/24 6:01:15 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRFX alert in real time by email
    SC 13G/A 1 zk2430799.htm SC 13G/A


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    _____________

    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)*

    PainReform Ltd.

    (Name of Issuer)

    Ordinary Shares, par value NIS 0.30 per share

    (Title of Class of Securities)

    M77798128

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☐ Rule 13d-1(b)
     
    ☐ Rule 13d-1(c)
     
    ☒ Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
    CUSIP No. M77798128
    13G
    Page 2 of 8 Pages

    1.
    Names of Reporting Persons.
     
    XT Hi-Tech Investments (1992) Ltd.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☐
    (b) ☐
    3.
    SEC Use Only
     
     
    4.
    Citizenship or Place of Organization
     
    Israel
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person with
    5.
    Sole Voting Power
     
    106,588 (1)
    6.
    Shared Voting Power
     
    0
    7.
    Sole Dispositive Power
     
    106,588 (1)
    8.
    Shared Dispositive Power
     
    0
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    106,588 (1)
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    5.2% (2)
    12.
    Type of Reporting Person (See Instructions)
     
    CO
     
    (1)
    On June 8, 2023, PainReform Ltd. (the “Issuer”) effected a reverse share split of its ordinary shares, par value NIS 0.30 per share (the “ordinary shares”), at the ratio of 1-for-10, such that each ten (10) ordinary shares were consolidated into one (1) ordinary share. Unless indicated otherwise by the context, all ordinary share amounts in this report have been adjusted to give effect to the reverse share split.
     
    (2)
    This percentage is based on 2,026,243 ordinary shares of the Issuer’s issued and outstanding share capital as of January 11, 2024, which number appeared in the Issuer’s registration statement on Form F-3, filed with the Securities and Exchange Commission (“SEC”) on January 12, 2024 (File No. 333-276485).

    2


    CUSIP No. M77798128
    13G
    Page 3 of 8 Pages

    1.
    Names of Reporting Persons.
     
    XT Holdings Ltd.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☐
    (b) ☐
    3.
    SEC Use Only
     
     
    4.
    Citizenship or Place of Organization
     
    Israel
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person with
    5.
    Sole Voting Power
     
    106,588 (1)
    6.
    Shared Voting Power
     
    0
    7.
    Sole Dispositive Power
     
    106,588 (1)
    8.
    Shared Dispositive Power
     
    0
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    106,588 (1)
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    5.2% (2)
    12.
    Type of Reporting Person (See Instructions)
     
    CO
     
    (1)
    Consists entirely of the 106,588 ordinary shares held by XT Hi-Tech Investments (1992) Ltd., which is an indirect, wholly-owned subsidiary of the Reporting Person with which the Reporting Person shares beneficial ownership as a result of the Reporting Person’s indirect, 100% control of the equity securities thereof. See Item 4.
     
    (2)
    This percentage is based on 2,026,243 ordinary shares of the Issuer’s issued and outstanding share capital as of January 11, 2024, which number appeared in the Issuer’s registration statement on Form F-3, filed with the SEC on January 12, 2024 (File No. 333-276485).
     
    3

     
    Item 1(a).  Name of Issuer:
     
    The name of the issuer is PainReform Ltd.
    ______________________________________________________________________________________________

    Item 1(b). Address of Issuer’s Principal Executive Offices:

    The Issuer’s principal executive offices are located at 65 Yigal Alon St., Tel Aviv, 6744316, Israel.
     ______________________________________________________________________________________________

    Item 2(a).  Name of Person Filing:
     
    The following entity and individuals, listed in (i)-(ii) below, who are filing this Statement of Beneficial Ownership on Schedule 13G (this “Statement”), are referred to herein collectively as the “Reporting Persons”:


    (i)
    XT Hi-Tech Investments (1992) Ltd. (“XT Hi-Tech”)

    (ii)
    XT Holdings Ltd. (“XT Holdings”)

    XT Hi-Tech is an indirect wholly owned subsidiary of XT Investments Ltd. (“XT Investments”), which is a direct wholly-owned subsidiary of XT Holdings, of which Orona Investments Ltd. (“Orona”) and Lynav Holdings Ltd. (“Lynav”) are each the direct owners of one-half of the outstanding ordinary shares. Orona is indirectly owned 56% by Mr. Udi Angel, who also indirectly owns 100% of the means of control of Orona. Lynav is held 95% by CIBC Bank and Trust Company (Cayman) Ltd. (“CIBC”)— as trustee of a discretionary trust established in the Cayman Islands. Udi Angel is member of the board of directors of XT Hi-Tech and has a casting vote with respect to various decisions taken by the board, including voting and disposition over the ordinary shares held by XT Hi-Tech.
     ______________________________________________________________________________________________

    Item 2(b).  Address of Principal Business Office or, if None, Residence:
     
    The principal business office of each Reporting Person is as follows:


    (i)
    XT Hi-Tech— 9 Andre Saharov Street, P.O. Box 15090, Haifa 31905, Israel

    (ii)
    XT Holdings— 9 Andre Saharov Street, P.O. Box 15090, Haifa 31905, Israel
    ______________________________________________________________________________________________

    Item 2(c).   Citizenship:

    The state of organization of each Reporting Person is as follows:


    (i)
    XT Hi-Tech — Israel

    (ii)
    XT Holdings — Israel
    ______________________________________________________________________________________________

    Item 2(d).    Title of Class of Securities:
     
    This Statement relates to the ordinary shares, par value New Israeli Shekel (“NIS”) 0.30 per share, of the Issuer.
    ______________________________________________________________________________________________

    Item 2(e).    CUSIP Number:

    The CUSIP number of the ordinary shares is M77798128.
    ______________________________________________________________________________________________

    4


    Item 3.
    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:

     
    (a)
    ☐
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
     
    (b)
    ☐
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
     
    (c)
    ☐
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
     
    (d)
    ☐
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e)
    ☐
    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
     
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
     
    (g)
    ☐
    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
    (h)
    ☐
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
     
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
    (j)
    ☐
    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
    (k)
    ☐
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).
     
                      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________________

       Not applicable.

    Item 4.          Ownership.



    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


    I.
    XT Hi-Tech
     

    (a)
    Amount beneficially owned: 106,588 ordinary shares

    (b)
    Percent of class*: 5.2%

    (c)
    Number of shares as to which the person has:

    (i)
    Sole power to vote or to direct the vote: 106,588

    (ii)
    Shared power to vote or to direct the vote: 0

    (iii)
    Sole power to dispose of or to direct the disposition of: 106,588

    (iv)
    Shared power to dispose of or to direct the disposition of: 0
     

    II.
    XT Holdings
     

    (a)
    Amount beneficially owned: 106,588 ordinary shares

    (b)
    Percent of class*: 5.2%

    (c)
    Number of shares as to which the person has:

    (i)
    Sole power to vote or to direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 106,588

    (iii)
    Sole power to dispose of or to direct the disposition of: 0

    (iv)
    Shared power to dispose of or to direct the disposition of: 106,588
     
    *          All percentages in this Schedule 13G are based on 2,026,243 ordinary shares of the Issuer’s issued and outstanding share capital as of January 11, 2024, which number appeared in the Issuer’s registration statement on Form F-3, filed with the SEC on January 12, 2024 (File No. 333-276485).
    5


    Item 5.          Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐.
                          ______________________________________________________________________________________________

    Item 6.          Ownership of More Than Five Percent on Behalf of Another Person.

    Each of (i) XT Investments, as the indirect parent company of XT Hi-Tech, (ii) XT Holdings, as the direct parent company of XT Investments, (iii) Orona and Lynav, as the direct owners of one-half of the outstanding ordinary shares of XT Holdings, and (iv) CIBC, as the holder of 95% of Lynav, have the right to receive dividends from, and proceeds from the sale of, the 106,588 ordinary shares held by XT Hi-Tech.
            ______________________________________________________________________________________________

    Item 7.          Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
     
                          Not applicable.
            ______________________________________________________________________________________________
     
    Item 8.          Identification and Classification of Members of the Group.
     
                          Not applicable.
            ______________________________________________________________________________________________
     
    Item 9.          Notice of Dissolution of Group.
     
                          Not applicable.
            ______________________________________________________________________________________________
     
    Item 10.        Certifications.
     
                          Not applicable.
            ______________________________________________________________________________________________
     
    6


    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    XT HI-TECH INVESTMENTS (1992) LTD.

    By: /s/ Assif Stoffman
    Name: Assif Stoffman
    Title: Vice President

    XT HOLDINGS LTD.

    By: /s/ Ori Angel
    Name: Ori Angel
    Title: Director

    Dated: January 23, 2024
    7

    EXHIBITS
     
    Exhibit 1 – Joint Filing Agreement pursuant to Rule 13d-1(k)(1)

    8

    Get the next $PRFX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRFX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRFX
    SEC Filings

    View All

    SEC Form 6-K filed by PainReform Ltd.

    6-K - PAINREFORM LTD. (0001801834) (Filer)

    10/1/25 9:29:56 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PainReform Ltd.

    6-K - PAINREFORM LTD. (0001801834) (Filer)

    8/19/25 8:45:37 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PainReform Ltd.

    6-K - PAINREFORM LTD. (0001801834) (Filer)

    8/13/25 4:16:22 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PainReform Provides Business Update for the Six Months Ended June 30, 2025

    TEL AVIV, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of AI-driven solar analytics technologies, today provided a business update for the six months ended June 30, 2025. Key Highlights: Completed majority investment in LayerBio, adding OcuRing™-K, a breakthrough dropless cataract therapy targeting a ~$9B global marketAdvanced PRF-110 with ongoing R&D following partially positive efficacy signals in postoperative painExpanded DeepSolar with completion of Smart Energy Management app, acceptance into NVIDIA Connect Program, and successful completion

    10/1/25 9:27:49 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform/DeepSolar Accepted into NVIDIA Connect Program

    TEL AVIV, Israel, Aug. 19, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), today announced that DeepSolar, PainReform's solar energy business unit developing next-generation AI-driven solar analytics, has been accepted into the prestigious NVIDIA Connect Program. This program is NVIDIA's premier development track for independent software vendors building transformative AI-based solutions across sectors. Participation in the program provides DeepSolar with access to NVIDIA's industry-leading AI frameworks, development tools, and engineering support. This future collaboration will support efforts to advance DeepSolar Predict, the company's breakthrough solar forecasting solution

    8/19/25 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

    TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), today announced, through its pharmaceutical division, the closing of its previously announced investment in LayerBio, Inc., a privately held Boston-based biotechnology company advancing sustained-release drug delivery technologies in ophthalmology. With this transaction, PainReform has acquired a majority equity interest in LayerBio and plans to initiate the next clinical trial of OcuRing™-K, LayerBio's lead investigational product for pain and inflammation control following cataract surgery. This transaction positions PainReform to potentially address a large and growing clinical need in the global catarac

    8/13/25 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Leadership Updates

    Live Leadership Updates

    View All

    PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

    HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.  Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri

    3/18/21 9:15:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

    HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing

    1/6/21 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/14/24 4:25:42 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/13/24 11:18:32 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by PainReform Ltd.

    SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)

    8/29/24 4:00:27 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care